本杰明｜20190408 未公开的英德战争在七国集团内部肆虐

2. 

   大虾 2
   2019年4月9日 下午8:53 3F
   登录回复

   最后说中国要卖神奇的蘑菇指什么，网页可能需要翻墙打不开

   • 

     盗版阴谋集团 5
     2019年4月10日 上午8:40 B1
     登录回复

     @ 大虾 我记得我在这个网站上发过翻墙指南的
     你应该可以自己解决
     我翻墙打开之后是这样
     还有一些图片发不过来
     Wuhan Enters Mushroom Psychedelic Medicine Market
     BARCELONA, Spain, April 05, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), announced today that its subsidiary MJ MedTech, Inc. (MJ MedTech) has created a new division dedicated to exploring opportunities in the psychedelic medicine space. The new division, M2BIO will be headed up by Wuhan’s CMO, Dr. Anna Morera Lorelta.
     According to Dr. Anna, psychedelic medicine is experiencing a remarkable revival in the wake of recent research studies and positive findings from great institutions, such as Johns Hopkins. Researchers are having great success in treating depression, post-traumatic stress disorder (PTSD), anxiety and certain addictions with Psilocybin, the active naturally occurring psychedelic pro-drug compound produced by specific mushrooms, known as “magic mushrooms”.
     Psilocybin therapy is a medical practice in which psilocybin, a psychoactive medicine, is administered to a patient during a session supported by a therapist. A psychoactive medicine is one that affects brain function and results in a change in cognition, perception or behavior.
     ”Psilocybin has become a very promising candidate for future treatments for anxiety and depression because it appears to disrupt the sorts of engrained brain activity patterns that are the hallmark of those diseases.” Said Dr. Anna.
     “Just like it took time for the regulators to get behind marijuana, we believe the same will happen with “magic mushrooms” in due course. We want to be far ahead of the curve and become pioneers in the market, collaborating with legislative bodies to help find better and healthier solutions,” added MJ MedTech CEO, Jeff Robinson.
     The new division, M2BIO aims to develop new therapies that will help patients who suffer from mental illness and ease the burden on healthcare systems globally. This division will be exploring additional indications for psilocybin, with the goal of bringing new therapies to market in the years to come.
     About Wuhan General Group (China), Inc.
     Wuhan General Group (China), Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that owns, develops and commercializes a range of CBD-based products. At Wuhan, our mission is to advance CBD-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies.
     For further information contact:
     Publicly traded company (OTC Pink: WUHN)
     Website: www.wuhn.org
     Public Relations E-mail: info@wuhn.org
     Forward-Looking Statements:
     Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
     Source: Wuhan General Group (China), Inc.
     Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post.

4. 

   太一之子 4
   2019年4月9日 下午1:07 2F
   登录回复

   以前聽我同學說武漢的製藥業很發達，武漢有很多制藥厂，他們的市場主要是國外

6. 

   太一之子 4
   2019年4月9日 下午12:56 1F
   登录回复

   神奇的蘑菇？

评论已关闭！